drugset / Trial / NCT01995058
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2014-02
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | Oral |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |